Search Results - "Bousquet, Peter F."

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor by Albert, Daniel H, Tapang, Paul, Magoc, Terrance J, Pease, Lori J, Reuter, David R, Wei, Ru-Qi, Li, Junling, Guo, Jun, Bousquet, Peter F, Ghoreishi-Haack, Nayereh S, Wang, Baole, Bukofzer, Gail T, Wang, Yi-Chun, Stavropoulos, Jason A, Hartandi, Kresna, Niquette, Amanda L, Soni, Nirupama, Johnson, Eric F, McCall, J Owen, Bouska, Jennifer J, Luo, Yanping, Donawho, Cherrie K, Dai, Yujia, Marcotte, Patrick A, Glaser, Keith B, Michaelides, Michael R, Davidsen, Steven K

“…ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor…”
Get full text

Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways by Chin, Chih-Liang, Pai, Madhavi, Bousquet, Peter F, Schwartz, Annette J, O'Connor, Elizabeth M, Nelson, Christine M, Hradil, Vincent P, Cox, Bryan F, McRae, Bradford L, Fox, Gerard B

“…Abstract USPIO-enhanced MRI allows non-invasive visualization of mononuclear cell infiltration into CNS lesions in MS and EAE. Herein, we show a distinct…”
Get full text

Discovery of N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor by Dai, Yujia, Hartandi, Kresna, Ji, Zhiqin, Ahmed, Asma A, Albert, Daniel H, Bauch, Joy L, Bouska, Jennifer J, Bousquet, Peter F, Cunha, George A, Glaser, Keith B, Harris, Christopher M, Hickman, Dean, Guo, Jun, Li, Junling, Marcotte, Patrick A, Marsh, Kennan C, Moskey, Maria D, Martin, Ruth L, Olson, Amanda M, Osterling, Donald J, Pease, Lori J, Soni, Niru B, Stewart, Kent D, Stoll, Vincent S, Tapang, Paul, Reuter, David R, Davidsen, Steven K, Michaelides, Michael R

“…In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a…”
Get full text

Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors by Dai, Yujia, Guo, Yan, Frey, Robin R, Ji, Zhiqin, Curtin, Michael L, Ahmed, Asma A, Albert, Daniel H, Arnold, Lee, Arries, Shannon S, Barlozzari, Teresa, Bauch, Joy L, Bouska, Jennifer J, Bousquet, Peter F, Cunha, George A, Glaser, Keith B, Guo, Jun, Li, Junling, Marcotte, Patrick A, Marsh, Kennan C, Moskey, Maria D, Pease, Lori J, Stewart, Kent D, Stoll, Vincent S, Tapang, Paul, Wishart, Neil, Davidsen, Steven K, Michaelides, Michael R

“…A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure−activity relationships at the 5-…”
Get full text

3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases by Ji, Zhiqin, Ahmed, Asma A, Albert, Daniel H, Bouska, Jennifer J, Bousquet, Peter F, Cunha, George, A, Diaz, Gilbert, Glaser, Keith B, Guo, Jun, Harris, Christopher M, Li, Junling, Marcotte, Patrick A, Moskey, Maria D, Oie, Tetsuro, Pease, Lori, Soni, Nirupama B, Stewart, Kent D, Davidsen, Steven K, Michaelides, Michael R

“…A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure–activity…”
Get full text

Thienopyridine urea inhibitors of KDR kinase by Heyman, H. Robin, Frey, Robin R., Bousquet, Peter F., Cunha, George A., Moskey, Maria D., Ahmed, Asma A., Soni, Niru B., Marcotte, Patrick A., Pease, Lori J., Glaser, Keith B., Yates, Melinda, Bouska, Jennifer J., Albert, Daniel H., Black-Schaefer, Candace L., Dandliker, Peter J., Stewart, Kent D., Rafferty, Paul, Davidsen, Steven K., Michaelides, Michael R., Curtin, Michael L.

“…The evaluation of KDR kinase inhibitor 2 (IC 50 = 9 nM) and related analogs is reported. A series of substituted thienopyridine ureas was prepared and…”
Get full text

1,4-Dihydroindeno[1,2-c]pyrazoles with Acetylenic Side Chains as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors with Low Affinity for the hERG Ion Channel by Dinges, Jürgen, Albert, Daniel H, Arnold, Lee D, Ashworth, Kimba L, Akritopoulou-Zanze, Irini, Bousquet, Peter F, Bouska, Jennifer J, Cunha, George A, Davidsen, Steven K, Diaz, Gilbert J, Djuric, Stevan W, Gasiecki, Alan F, Gintant, Gary A, Gracias, Vijaya J, Harris, Christopher M, Houseman, Kathryn A, Hutchins, Charles W, Johnson, Eric F, Li, Hu, Marcotte, Patrick A, Martin, Ruth L, Michaelides, Michael R, Nyein, Michelle, Sowin, Thomas J, Su, Zhi, Tapang, Paul H, Xia, Zhiren, Zhang, Henry Q

“…The synthesis of a novel series of 1,4-dihydroindeno[1,2-c]pyrazoles with acetylene-type side chains is described. Optimization of those compounds as KDR…”
Get full text

Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2- c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors by Akritopoulou-Zanze, Irini, Albert, Daniel H., Bousquet, Peter F., Cunha, George A., Harris, Christopher M., Moskey, Maria, Dinges, Jurgen, Stewart, Kent D., Sowin, Thomas J.

“…We report the synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2- c]pyrazoles as multitargeted kinase inhibitors. Initial efforts…”
Get full text

Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases by Ji, Zhiqin, Ahmed, Asma A., Albert, Daniel H., Bouska, Jennifer J., Bousquet, Peter F., Cunha, George A., Glaser, Keith B., Guo, Jun, Li, Junling, Marcotte, Patrick A., Moskey, Maria D., Pease, Lori J., Stewart, Kent D., Yates, Melinda, Davidsen, Steven K., Michaelides, Michael R.

“…A series of isothiazolopyrimidines and isoxazolopyrimidines were synthesized and identified as potent RTK inhibitors. SAR studies led to isothiazolopyrimidine…”
Get full text

Hit-to-lead optimization of 1,4-dihydroindeno[1,2- c]pyrazoles as a novel class of KDR kinase inhibitors by Dinges, Jürgen, Akritopoulou-Zanze, Irini, Arnold, Lee D., Barlozzari, Teresa, Bousquet, Peter F., Cunha, George A., Ericsson, Anna M., Iwasaki, Nobuhiko, Michaelides, Michael R., Ogawa, Nobuo, Phelan, Kathleen M., Rafferty, Paul, Sowin, Thomas J., Stewart, Kent D., Tokuyama, Ryukou, Xia, Zhiren, Zhang, Henry Q.

“…A series of 1,4-dihydroindeno[1,2- c]pyrazoles was evaluated as KDR kinase inhibitors. Hit-to-lead optimization studies led to 19, a lead compound with an…”
Get full text

1,4-Dihydroindeno[1,2- c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors by Dinges, Jürgen, Ashworth, Kimba L., Akritopolou-Zanze, Irini, Arnold, Lee D., Baumeister, Steven A., Bousquet, Peter F., Cunha, George A., Davidsen, Steven K., Djuric, Stevan W., Gracias, Vijaya J., Michaelides, Michael R., Rafferty, Paul, Sowin, Thomas J., Stewart, Kent D., Xia, Zhiren, Zhang, Henry Q.

“…A series of 1,4-dihydroindeno[1,2- c]pyrazoles with urea-type side chains was identified as potent multitargeted (VEGFR and PDGFR families) receptor tyrosine…”
Get full text

Isoindolinone ureas: a novel class of KDR kinase inhibitors by Curtin, Michael L, Frey, Robin R, Heyman, H.Robin, Sarris, Kathy A, Steinman, Douglas H, Holmes, James H, Bousquet, Peter F, Cunha, George A, Moskey, Maria D, Ahmed, Asma A, Pease, Lori J, Glaser, Keith B, Stewart, Kent D, Davidsen, Steven K, Michaelides, Michael R

“…The evaluation of KDR kinase inhibitor 4e (IC 50 7 nM) and related analogs is reported. A series of substituted isoindolinone ureas was prepared and evaluated…”
Get full text

Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity by BOUSQUET, P. F, BRANA, M. F, KEILHAUER, G, ROMERDAHL, C. A, CONLON, D, FITZGERALD, K. M, PERRON, D, COCCHIARO, C, MILLER, R, MORAN, M, GEORGE, J, XIAO-DONG QIAN

“…LU 79553 is a novel bis-naphthalimide which is highly cytotoxic in vitro with EC50 (concentration required for 50% inhibition of growth) ranging from 2 x…”
Get full text

Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma by BOUSQUET, P. F, PAULSEN, L. A, FONDY, C, LIPSKI, K. M, LOUCY, K. J, FONDY, T. P

“…Cytochalasin B (CB), at 100 or at 10 mg/kg single dose s.c. in carboxymethyl-cellulose (2%)/Tween-20 (1%) 24 h after s.c. challenge of B6D2F1 mice with trocar…”
Get full text

Corrigendum to “1,4-Dihydroindeno[1,2- c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors” [Bioorg. Med. Chem. Lett. 16 (2006) 4266–4271] by Dinges, Jürgen, Ashworth, Kimba L., Akritopoulou-Zanze, Irini, Arnold, Lee D., Baumeister, Steven A., Bousquet, Peter F., Cunha, George A., Davidsen, Steven K., Djuric, Stevan W., Gracias, Vijaya J., Michaelides, Michael R., Rafferty, Paul, Sowin, Thomas J., Stewart, Kent D., Xia, Zhiren, Zhang, Henry Q.

Get full text

Benzimidazo[1,2-c]quinazoline dimers as potential antitumor agents by Braña, Miguel F., de Vega, María Jesús Pérez, Perron, Denise, Conlon, Donna, Bousquet, Peter F., Robinson, Simon P.

“…The 6‐substituted benzimidazo[1,2‐c]quinazoline 1 is a lead structure from our DNA intercalator program and is cytotoxic to the human colon cancer tumor line…”
Get full text